Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AG-2404
- Development stage
- Preclinical
- Lead developer
- AHN-GOOK PHARMACEUTICAL
- Modality
- Small Molecules
01
Overview
AG-2404 is an Improved New Drug (IMD) candidate currently in the research stage of development by Ahn-Gook Pharmaceuticals. It is being developed for the treatment of cardiovascular diseases. In the South Korean regulatory framework, an IMD (also referred to as an Incrementally Modified Drug) is a medication that has been modified from a previously approved drug to provide clinical improvements, such as enhanced efficacy, reduced side effects, or improved patient convenience. These modifications can include new formulations, new salts, or fixed-dose combinations. Specific details regarding the active ingredients or molecular targets of AG-2404 have not yet been disclosed by the developer.
Beyond the preview
Go deeper on AG-2404.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AG-2404.